Use of Polygenic Risk Scores for Coronary Heart Disease in Ancestrally Diverse Populations
Ozan Dikilitas1,2,3, Daniel J Schaid4, Catherine Tcheandjieu5,6
1Department of Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA.
Insights
Polygenic risk scores (PRS) for coronary heart disease (CHD) work well in European populations but less effectively in others. Improving PRS for diverse ancestries is crucial for equitable genomic medicine.
Area of Science:
- Genetics
- Genomic Medicine
- Cardiovascular Disease Research
Background:
- Polygenic risk scores (PRS) quantify genetic liability for diseases.
- Current PRS for coronary heart disease (CHD) primarily use European ancestry data.
- Performance variation across ancestries limits equitable clinical application.
Purpose of the Study:
- To review the performance of CHD PRS across diverse populations.
- To explore methods for improving PRS applicability in non-European ancestries.
- To address the need for equitable implementation of genomic medicine.
Main Methods:
- Review of existing literature on PRS performance in various ancestry groups.
- Examination of novel population and statistical genetics approaches.
- Analysis of strategies like fine-mapping and trans-ancestry meta-analyses.
Main Results:
- CHD PRS demonstrate robust performance in European ancestry cohorts.
- Performance significantly lags in non-European groups, especially those of African ancestry.
- Established consortia are developing methods to enhance multi-ancestry PRS performance.
Conclusions:
- Variable PRS performance in non-European groups hinders clinical enthusiasm.
- Increased diversity in genomic studies is essential.
- Methodological innovation is required for equitable PRS implementation in genomic medicine.
Purpose Of Review:
A polygenic risk score (PRS) is a measure of genetic liability to a disease and is typically normally distributed in a population. Individuals in the upper tail of this distribution often have relative risk equivalent to that of monogenic form of the disease. The majority of currently available PRSs for coronary heart disease (CHD) have been generated from cohorts of European ancestry (EUR) and vary in their applicability to other ancestry groups. In this report, we review the performance of PRSs for CHD across different ancestries and efforts to reduce variability in performance including novel population and statistical genetics approaches.
Recent Findings:
PRSs for CHD perform robustly in EUR populations but lag in performance in non-EUR groups, particularly individuals of African ancestry. Several large consortia have been established to enable genomic studies in diverse ancestry groups and develop methods to improve PRS performance in multi-ancestry contexts as well as admixed individuals. These include fine-mapping to ascertain causal variants, trans ancestry meta-analyses, and ancestry deconvolution in admixed individuals. PRSs are being used in the clinical setting but enthusiasm has been tempered by the variable performance in non-EUR ancestry groups. Increasing diversity in genomic association studies and continued innovation in methodological approaches are needed to improve PRS performance in non-EUR individuals for equitable implementation of genomic medicine.
More Related Videos
Related Concept Videos
Polygenic Traits
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Coronary Artery Disease I: Introduction
Relative Risk
Heritability


